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ABSTRACT: Introduction: ACT DMD was a 48-week trial of ataluren
for nonsense mutation Duchenne muscular dystrophy (nmDMD).
Patients received corticosteroids for ≥6 months at entry and stable
regimens throughout study. This post hoc analysis compares efﬁcacy

Additional supporting information may be found in the online version of
this article.
Abbreviations: 6MWD, 6-minute walk distance; 6MWT, 6-minute walk
test; ACT DMD, Ataluren Conﬁrmatory Trial in Duchenne muscular dystrophy; BMI, body mass index; CL, conﬁdence limit; CINRG-DNHS, Cooperative International Neuromuscular Research Group-Duchenne Natural
History Study; DMD, Duchenne muscular dystrophy; FOR-DMD, Finding
the Optimum Regimen for Duchenne muscular dystrophy; HRQoL, healthrelated quality of life; ITT, intent-to-treat; LoA, loss of ambulation; LS, least
square; MMRM, mixed model repeated measures; nm, nonsense mutation; NSAA, North Start Ambulatory Assessment; PODCI, Pediatric Outcomes Data Collection Instrument; SEA, severe adverse event; TEAE,
treatment-emergent adverse event; TFT, Timed Function Test
Key words: deﬂazacort, muscular dystrophy, prednisolone, prednisone,
walking
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and safety for deﬂazacort and prednisone/prednisolone in the placebo arm. Methods: Patients received deﬂazacort (n = 53) or prednisone/prednisolone (n = 61). Endpoints included change from
baseline in 6-minute walk distance (6MWD), timed function tests, estimated age at loss of ambulation (extrapolated from 6MWD). Results:
Mean changes in 6MWD were -39.0 m (deﬂazacort; 95% conﬁdence
limit [CL], -68.85, -9.17) and -70.6 m (prednisone/prednisolone; 95%
CL, -97.16, -44.02). Mean changes in 4-stair climb were 3.79 s (deﬂazacort; 95% CL, 1.54, 6.03) and 6.67 s (prednisone/prednisolone;
95% CL, 4.69, 8.64). Conclusions: This analysis, limited by its post
hoc nature, suggests greater preservation of 6MWD and 4-stair climb
with deﬂazacort vs. prednisone/prednisolone. A head-to-head comparison will better deﬁne these differences.
Muscle Nerve 58:639–645, 2018

Duchenne muscular dystrophy, a rare, irreversible,
X-linked disorder, results in a progressive decline in muscle function and when left untreated, leads to loss of
ambulation (LoA) by age 10–12 years and death from cardiac or respiratory failure by the late teens to approximately 25 years of age.1–5 The current standard of care
for DMD includes corticosteroid therapy with prednisone, prednisolone, or deﬂazacort,2 with accumulating
evidence suggesting that these agents can slow the decline
in muscle strength and motor function, delay LoA, possibly decrease the development of scoliosis requiring operative management, and slow the loss of upper limb
function and the rate of pulmonary function decline.5–8
Deﬂazacort is a synthetic corticosteroid characterized
by the insertion of a fused methyl-oxazoline ring in the
chemical structure of prednisone, with a long duration
of action.9 A phase 3, randomized, double-blind,
placebo-controlled, 12-week trial of 2 doses of deﬂazacort
(0.9 mg/kg/d and 1.2 mg/kg/d) or prednisone dosed
at 0.75 mg/kg/d showed that each dosage level of deﬂazacort or prednisone increased muscle strength from
baseline compared with placebo in just 12 weeks.10
The objective of this post hoc analysis from a previously published study11 is to compare the efﬁcacy and
safety of deﬂazacort and prednisone/prednisolone in
slowing DMD disease progression as it relates to physical functioning and the potential for delay in LoA.
MATERIALS AND METHODS

Study Design. The Ataluren Conﬁrmatory Trial in
patients with nonsense mutation DMD (nmDMD) (ACT
MUSCLE & NERVE
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DMD, NCT01826487) study was a randomized, double-blind,
placebo-controlled 48-week trial that evaluated ataluren’s
treatment effect in stabilizing motor function and delaying disease progression in patients with nmDMD.11
All patients enrolled in this study had been receiving corticosteroid therapy (deﬂazacort or prednisone/prednisolone)
for ≥6 months at study entry, had no clinically signiﬁcant
change in dosage or dosing regimen for ≥3 months before
study entry, and were expected to maintain a stable dose and
regimen during the study.11 Dosing alterations necessitated by
changes in body weight were allowed. The placebo arm consisted of 114 patients in the intent-to-treat (ITT) population,
53 of whom received deﬂazacort and 61 of whom received
prednisone/prednisolone at entry and throughout the study.
The size of these subgroups made a comparison of ﬁndings
with these corticosteroids feasible. The present analysis was
conducted using data from the placebo arm of the ACT DMD
trial.
Patients. This phase 3 study enrolled ambulatory male
patients with phenotypic and genotypic conﬁrmation of
nmDMD aged 7–16 years. Inclusion and exclusion criteria
were as described previously.11
Parents or guardians provided written informed consent,
and patients provided written assent when appropriate. The
trial and any changes to the protocol were approved by the
local regulatory authorities and the institutional review board
of each site. The trial was done in accordance with the Declaration of Helsinki (2000) and the principles of Good Clinical
Practice, according to the International Council for Harmonisation tripartite guideline.
Efﬁcacy Endpoints. Efﬁcacy assessments were conducted
every 8 weeks at clinic visits.12 The primary endpoint assessed
the ability of treatment to slow the progression of disease and
was evaluated by the change from baseline to Week 48 in
6-minute walk distance (6MWD). The secondary endpoints
evaluated the effect of treatment on proximal muscle function
using Timed Function Tests (TFTs; 4-stair climb/descent, rise
from supine, 10 m walk/run). Exploratory assessments consisted of the North Star Ambulatory Assessment (NSAA) and
Pediatric Outcomes Data Collection Instrument (PODCI)
domains of Transfer/Basic Mobility and Sports/Physical Functions.11 The NSAA is a validated, DMD-speciﬁc scale shown to
be sensitive to change. It evaluates 17 functional abilities relevant to ambulant patients and scores these as 0, unable to perform; 1, performs with difﬁculty; or 2, able to perform for a
total score from 0 (worst) to 34 (best).12–15 The PODCI evaluates health-related quality-of-life (HRQoL) outcomes with
each domain scored from 0 (worst) to 100 (best).11,16 The
PODCI was developed to evaluate functional outcomes of
musculoskeletal health in children and adolescents and has
been shown to be reliable and have valid construct and sensitivity to change.16
Safety Endpoints. Safety assessments included type, frequency, severity, timing, and relationship to study drug of
adverse events that were recorded throughout the study, laboratory abnormalities and changes in vital signs assessed every
8 weeks, and ﬁndings from physical examinations at 24 and
48 weeks.11
Statistical Analyses. In this analysis, corticosteroid efﬁcacy data were analyzed for the ITT population, consisting
of all patients who were randomized to placebo and who
640

had a valid 6MWD value at baseline and ≥1 valid post-baseline 6MWD assessment.12 Comparisons were made according to corticosteroid treatment at baseline (deﬂazacort
vs. prednisone/prednisolone).
The analysis used mixed model repeated measures
(MMRM) with multiple imputation for missing data values
using SAS programs Proc MI to create multiple imputed
datasets and Proc MIANALYZE to combine the inferences
from each dataset into a single one. The model included the
following factors: age (<9 years, ≥9 years), baseline 6MWD
(<350 m, ≥350 m), duration of prior corticosteroid
(≥6 months to <12 months, ≥12 months), corticosteroid subgroup (deﬂazacort, prednisone/prednisolone), visit (as a
class variable), interaction of visit with previously mentioned
factors, baseline value as a covariate, and interaction of visit
with baseline value. Least square means for changes in
6MWD and TFTs from baseline to study end and treatment
differences were calculated. For patients who were unable to
perform the 6-minute walk test (6MWT) at a study visit, a
value of 0 m was assigned. For patients who were unable to
perform a TFT and for those whose performance was >30 s,
a value of 30 s was assigned. Standardized t-statistics were
used to allow for the reporting of multiple endpoints
(6MWD, TFTs, and the NSAA and PODCI scores) on the
same scale on a Forest plot. Values were calculated by dividing the point estimate for the difference between deﬂazacort
vs. prednisone/prednisolone in mean change at Week
48, and the 95% conﬁdence limits (CL), each by the standard error. For endpoints where improved function is represented by a negative value (i.e., TFTs), the signs of the values
were reversed.
For determination of LoA, the 48-week changes from baseline in 6MWD observed in patients taking deﬂazacort or prednisone/prednisolone were annualized. For patients who did
not reach LoA by Week 48, linear extrapolation was used to
estimate the number of years it would take to reach LoA
(a 6MWD of 0 m) according to the method of Clayton and
colleagues.17 This model, however, does not consider the
potential nonlinear decline in 6MWD in older patients with
DMD.18
The duration of exposure to either corticosteroid before
study entry was determined using the following assumptions:
(1) if end date of corticosteroid therapy before study entry
was missing, the end date was noted as the start date of placebo; (2) if end date of corticosteroid therapy before study
entry was on or after the start date of placebo, the end of
corticosteroid therapy was noted as the start date of
placebo.
Safety was analyzed in the as-treated population, which consisted of all randomized patients who received any study
treatment.12

RESULTS
Patients.

A total of 115 patients enrolled in the
ACT DMD trial were randomized to placebo.11 The
ITT population for the placebo arm consisted of
114 patients, with 53 patients receiving deﬂazacort
and 61 receiving prednisone/prednisolone. One
patient with a valid post-baseline 6MWD was discontinued because gene sequencing did not conﬁrm the
presence of a nonsense mutation in the dystrophin
gene.11

Deﬂazacort versus Prednisone/Prednisolone: ACT DMD Trial Analysis
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Table 1. Baseline patient demographics (ITT population)

Characteristic
Age, y
Mean (SD)
Range
Age group, n (%)
<9 y
≥9 y
Race, n (%)
White
Black/African American
Asian
Hispanic
Other
Missing
Weight, kg
Mean (SD)
Range
Height, cm
Mean (SD)
Range
BMI, kg/m2
Mean (SD)
Range
Corticosteroid
use prior
to baseline, n (%)
6 to <12 months
≥12 months

Deﬂazacort
(n = 53)

Prednisone/
prednisolone
(n = 61)

Total
(n = 114)

9.2 (1.7)
7,14

8.8 (1.6)
7,13

9.0 (1.7)
7,14

23 (43.4)
30 (56.6)

30 (49.2)
31 (50.8)

53 (46.5)
61 (53.5)

46 (86.8)
0 (0.0)
4 (7.5)
3 (5.7)
0 (0.0)
0 (0.0)

40 (63.9)
1 (1.6)
2 (3.3)
5 (8.2)
4 (6.6)
10 (16.4)

85 (74.6)
1 (0.9)
6 (5.3)
8 (7.0)
4 (3.5)
10 (8.8)

30.9 (11.9)
18.1, 68.0

30.5 (9.2)
18.2, 59.8

30.7 (10.5)
18.1, 68.0

127.010.6)
106.7, 148.7

125.7 (10.4)
101.8, 151.0

126.3 (10.4)
101.8, 151.0

18.6 (4.70)
13.0, 36.0

19.0 (3.5)
13.1, 27.1

18.9 (4.1)
13.0, 36.0

7 (13.2)
46 (86.8)

11 (18.0)
50 (82.0)

18 (15.8)
96 (84.2)

SD, standard deviation.

The characteristics (Table 1 and Supplementary
Table S1, which is available online) of the patients taking either deﬂazacort or prednisone/prednisolone
were well balanced at baseline. These patients had a
mean age of 9 years, and most of these patients had
been receiving corticosteroid therapy for ≥12 months
before entering the study.
There was no signiﬁcant difference in the duration
of exposure to deﬂazacort or prednisone before study
entry. Patients treated with deﬂazacort had a mean
exposure of 1062 days (range, 189–2743 days), and
those treated with prednisone/prednisolone had a
mean exposure of 1081 days (range, 124–2698 days;
P = 0.86, t-test) before study entry.
Dosing data in mg/kg/day were available for
110 patients. For the other 4 patients in the ITT population, the dosing record described liquid volume or
number of drops of suspension without drug concentration, and, therefore, these patients were excluded
from the summary of dosing. In the prednisone/prednisolone subgroup, dosing regimens consisted of daily
(64.4%), every other day (16.9%), 10 days on followed
by 10 days off (10.2%), and high-dose weekend
(8.5%). In the deﬂazacort subgroup, dosing regimens
consisted of daily (84.3%), every other day (13.7%),
and twice a day (2.0%). Among patients on a daily dosing regimen, the mean dose was relatively lower for
prednisone/prednisolone (0.515 mg/kg/day, recommended 0.75 mg/kg/day, 69% of recommended)
Deﬂazacort versus Prednisone/Prednisolone: ACT DMD Trial Analysis

than deﬂazacort (0.695 mg/kg/day, recommended
0.9 mg/kg/day, 77% of recommended).
Physical Functioning. Patients treated with deﬂazacort had notably less decline from baseline in 6MWD
at Week 48 than those treated with prednisone/
prednisolone (Table 2; Fig. 1). The extrapolated
time to loss of ambulation when using a linear model
was 8.58 years for deﬂazacort and 4.74 years with
prednisone/prednisolone, a noteworthy difference.
Results for the 4-stair climb showed that the LS
mean increase in time from baseline to Week 48 with
deﬂazacort was approximately half of that with prednisone/prednisolone, (Table 2; Fig. 1). For the other
TFTs (4-stair descend, rise from supine, 10-m walk/
run) and the NSAA total score, LS mean changes
also notably favored deﬂazacort (Table 2; Fig. 1).
The mean decline in the domain of Sports/Physical Function in HRQoL for the patients receiving
deﬂazacort was less than that for the patients receiving prednisone/prednisolone (Table 2). The treatment difference for the Transfers/Basic Mobility
domain of the PODCI also favored deﬂazacort.

The safety proﬁles for deﬂazacort and prednisone/prednisolone were generally comparable. No signiﬁcant differences were noted. Table 3 lists treatmentemergent adverse events (TEAEs) occurring in either
subgroup with an incidence >5%. The incidence of the
following TEAEs was numerically lower for the deﬂazacort subgroup than for the prednisone/prednisolone
subgroup: nasopharyngitis, abdominal pain, back pain,
pyrexia, and upper respiratory tract infection. The
remaining TEAEs were similar between the

Safety.

Table 2. Least squares mean change (95% CL) from baseline to
week 48 in assessments of physical functioning and HRQoL
(ITT)

Endpoint
Δ (SE)
(95% CL)

Deﬂazacort
(n = 53)

Prednisone/
prednisolone
(n = 61)

Difference
(95% CL)

−39.01 (15.05) −70.59 (13.40)
31.6
(−68.85, −9.17) (−97.16, −44.02) (0.22, 62.94)

6MWD, m
TFTs, s
4-Stair climb

3.79 (1.13)
(1.54, 6.03)
3.89 (1.29)
(1.33, 6.45)
4.50 (1.24)
(2.05, 6.95)
3.16 (0.93)
(1.32, 5.00)
−3.39 (0.70)
(−4.78, −2.01)

4-Stair descent
Rise from supine
10-m walk/run
NSAA total score
PODCI
Sports/Physical Functioning
Transfers/Basic/Mobility

6.67 (1.0)
(4.69, 8.64)
5.66 (1.12)
(3.43, 7.89)
7.10 (1.13)
(4.86, 9.34)
3.25 (0.85)
(1.56, 4.94)
−4.53 (0.66)
(−5.83, −3.23)

−4.80 (2.49)
−10.76 (2.25)
(−9.73, 0.13) (−15.21, −6.31)
−7.53 (2.62)
−9.20 (2.34)
(−12.72, −2.35) (−13.84, −4.57)

−2.88
(−5.27, −0.48)
−1.77
(−4.51, 0.98)
−2.60
(−5.20, 0.01)
−0.09
(−2.07, 1.89)
1.14
(−0.36, 2.64)
5.96
(0.65, 11.28)
1.67
(−3.87, 7.21)

Δ, mean change.

MUSCLE & NERVE

November 2018

641

FIGURE 1. Least-square mean changes and t-statistics from baseline to week 48 in assessments of physical functioning and HRQoL
(ITT) for deﬂazacort versus prednisone/prednisolone.

2 subgroups, with none being markedly lower in the
prednisone/prednisolone subgroup.
Patients in the placebo arm receiving deﬂazacort
had numerically smaller increases in weight, height,
and BMI during the study than patients receiving
prednisone/prednisolone (Table 4).
Most TEAEs were mild to moderate in severity and
included a mild T12 vertebral fracture in a patient treated with deﬂazacort. Severe AEs consisted of 1 case
each of back pain and vomiting in the deﬂazacort subgroup and 1 case each of gait disturbance and muscular
weakness in the prednisone/prednisolone subgroup. A
total of 4 patients had serious adverse events (SAEs). In
the deﬂazacort subgroup, the 3 SAEs included myocarditis, abnormal hepatic function test, and femur and
lower limb fractures. The fourth SAE, which occurred
in the prednisone/prednisolone subgroup, was

gastroenteritis. One patient receiving deﬂazacort and
none of the patients receiving prednisone/prednisolone discontinued the trial due to loss of ambulation.
DISCUSSION

This post hoc analysis of the placebo arm of the ACT
DMD study demonstrated less mean decline from
baseline to week 48 in 6MWD, lower mean declines
from baseline in the 4-stair climb and the PODCI
domain of Sports/Physical Function in HRQoL, and
a longer estimated duration of ambulation in patients
treated with deﬂazacort than with prednisone/prednisolone. Current practice guidelines recommend
use of corticosteroids for their beneﬁts on muscle
strength and motor function and delay in LoA in
patients with DMD.2 Although their mechanism of
action in DMD is not completely understood, the

Table 3. Most common* TEAEs (as-treated population)

TEAE, n (%)
Pain in abdomen
(including upper
abdomen)
Nasopharyngitis
Headache
Vomiting
Fall
Pain in extremity
Cough
Pyrexia
Constipation
Back pain
Upper respiratory
tract infection
Diarrhea
Ligament sprain
Nausea
Oropharyngeal pain

Deﬂazacort
(n = 53)

Prednisone/Prednisolone
(n = 62)

0 (0)

18 (29)
Measurement

6 (11)
10 (19)
10 (19)
8 (15)
6 (11)
5 (9)
4 (8)
4 (8)
2 (4)
0 (0)

17 (27)
11 (18)
11 (18)
12 (19)
8 (13)
8 (13)
8 (13)
6 (10)
6 (10)
6 (10)

5 (9)
3 (6)
3 (6)
2 (4)

5 (8)
4 (6)
4 (6)
4 (6)

*Incidence of ≥5% in either subgroup.
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Table 4. Mean changes from baseline in weight, height, and BMI
at week 48

Weight, kg
n
Mean change (SD)
95% CL
Median
Height, cm
n
Mean change (SD)
95% CL
Median
BMI, kg/m3
n
Mean change (SD)
95% CL
Median

Deﬂazacort
(n = 53)

Prednisone/prednisolone
(n = 62)

50
3.9 (2.6)
3.2, 4.6
3.8

59
4.6 (3.2)
3.8, 5.4
3.8

50
3.2 (2.0)
2.7, 3.8
3.0

59
3.9 (1.9)
3.4, 4.4
4.0

50
1.3 (1.3)
1.0, 1.7
1.3

59
1.6 (1.5)
1.2, 1.9
1.4

CI, conﬁdence limit; SD, standard deviation.

Deﬂazacort versus Prednisone/Prednisolone: ACT DMD Trial Analysis
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anti-inﬂammatory properties of these agents have
been implicated along with stabilizing effects on muscle ﬁber membranes, inhibition of muscle proteolysis, stimulation of myoblast proliferation, and
differential gene regulation.5–7
The 6MWT is a globally accepted assessment of
endurance and muscle function in patients with neuromuscular diseases who are capable of ambulation.19,20 The treatment difference observed in this
study between deﬂazacort and prednisone/prednisolone for the 6MWT was associated with a 95% CL with
a lower limit that approached 0. However, the magnitude of the difference was substantially larger than the
published standards for a clinically meaningful difference. A 6MWD change of 10 to 20 m is clinically
meaningful across a wide range of ambulatory patients
with DMD.21 The treatment difference observed in
this post hoc analysis for the 4-stair climb also meets
published standards for a clinically meaningful minimal difference of 1.5 s.22
Prolonging ambulation is a key goal of treatment.2
Loss of ambulation constitutes a substantial disability
for DMD patients and it marks the beginning of a
more severe stage of the disease. Delaying LoA has
been correlated with delaying the time to loss of subsequent disease milestones such as decline in respiratory function.8,23
The ﬁnding for LoA in this post hoc analysis is consistent with data from the large (N = 340), observational,
Cooperative International Neuromuscular Research
Group-Duchenne Natural History Study (CINRGDNHS), in which deﬂazacort further delayed LoA by
nearly 3 years compared with prednisone/prednisolone
(daily regimen) 24 and those from a more recently published, long-term, prospective, cohort study from
CINRG (N = 440) that showed further delays of
2.7 years in LoA with deﬂazacort compared with prednisone/prednisolone.8
The DMD Care Considerations guidelines recommend daily dosing of patients with DMD with corticosteroids unless the therapy is not well tolerated, in
which case an alternative regimen may be used.2 The
most common corticosteroid dosing regimen for
patients in the placebo arm of the ACT DMD trial
was once daily. There was a higher percentage of
patients on daily deﬂazacort therapy compared with
patients receiving daily prednisone/prednisolone. A
possible reason for this observation may be that daily
therapy with deﬂazacort was better tolerated in these
patients than daily therapy with prednisone/prednisolone. This reasoning may also be supported by the
fact that the daily mean dose was higher relative to
the recommended dose for deﬂazacort than for prednisone/prednisolone. The corticosteroid regimens
were determined by the patients’ physicians before
the study and are thus representative of real-world
use of these agents.
Deﬂazacort versus Prednisone/Prednisolone: ACT DMD Trial Analysis

Deﬂazacort treatment in this post hoc analysis was
associated with slightly lower mean growth over
48 weeks than treatment with prednisone/prednisolone. Corticosteroid effects on growth may inﬂuence
delay of LoA, possibly by conferring biomechanical
advantages for walking.25,26 A prospective, longitudinal, multicenter study in the United Kingdom
observed a possible link between shorter stature and
delayed LoA in patients with DMD receiving corticosteroids.15 An analysis of anthropomorphic effects
found that patients treated with deﬂazacort had significantly shorter stature (P < 0.002) than those treated
with prednisone over a 52-week follow-up.2,6
Weight gain may contribute to disability in
patients with DMD by increasing the load on deteriorating muscles. Corticosteroid therapy has been associated with weight gain, and some studies in patients
with DMD have noted less weight gain with deﬂazacort than with prednisone, including an analysis of
anthropomorphic effects of corticosteroid therapy in
DMD26 and a systematic review of clinical trials of
corticosteroid treatment in patients with DMD.7 Consistent with these studies, patients receiving deﬂazacort in this post hoc analysis had a lower mean
increase in weight than those receiving prednisone/
prednisolone and a smaller mean increase in BMI.
Other adverse effects of corticosteroid therapy in
DMD clinical trials include behavioral abnormalities,
cushingoid appearance, excessive hair growth, and
cataracts.6,7 Deﬂazacort has been associated with a
lower incidence of these events, with the exception
of cataracts.6 None of these events were reported for
patients in the placebo arm of the ACT DMD trial.
This analysis has several limitations, including its
post hoc nature and the fact that the ACT DMD trial
was not powered to detect speciﬁc treatment differences in these subgroups of the placebo arm. For
rare diseases, retrospective analyses can provide
insights and contribute to the body of data on medical interventions. Because deﬂazacort was not commercially available in the United States until 2017,27
a potential confounder of this post hoc analysis is
that in the United States, patients with DMD who
were treated with deﬂazacort could have been from
families of high socioeconomic means and may have
been receiving better supportive care, which may
have affected the outcomes of this analysis. However,
of the 230 total patients in ACT DMD, 162 were
from outside the United States (70.4%). The placebo
arm, which was the source of the data for this post
hoc analysis, had 115 total patients in the as-treated
population. Eighty-three of the 115 total patients in
the placebo arm were from outside the United
States, (72.2%), with 37 of the 83 treated with deﬂazacort while 46 received prednisone. Only 32 patients
of the 115 total patients were from the United States,
with 16 of the 32 treated with deﬂazacort while the
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remaining 16 patients were treated with prednisone.
The treatment beneﬁts observed in patients who
received deﬂazacort in this study are, therefore, not
likely attributable to socioeconomic status, as most of
the study subjects were from outside the United
States, where deﬂazacort was and remains readily
available as a generic drug. Additionally, the inclusion criterion of a 6MWD ≤ 80% of predicted for the
ACT DMD trial made it possible to enroll patients
with a wide range of disease severity, which is representative of patients in the real world. As mentioned
previously, the baseline characteristics of the patients
from the deﬂazacort and prednisone/prednisolone
groups were comparable.
Additional evidence comparing the beneﬁts of deﬂazacort and prednisone/prednisolone in patients with
DMD may become available from an analysis of data
from the placebo arm of a 48-week, phase 3, randomized, double-blind, placebo-controlled trial that evaluated the efﬁcacy and safety of treatment with tadalaﬁl
for prolonging ambulation. This study had the same
requirements for corticosteroid therapy before and
during the trial as those in the ACT DMD trial. The
ongoing international, multicenter, double-blind,
parallel-group, 3-year Finding Optimum Regimen for
DMD (FOR-DMD) trial (NCT01603407) 28 comparing
daily and intermittent regimens of prednisone to daily
deﬂazacort in approximately 300 patients with DMD
may further augment the understanding of beneﬁts
associated with these 2 steroid treatments and 2 regimens (daily versus intermittent). However, it is noteworthy that this trial has focused on a younger cohort
of patients with DMD ages 4 to 6 years who are not
necessarily expected to experience functional deterioration while on steroids.
In conclusion, these ﬁndings suggest that deﬂazacort therapy may confer beneﬁts as compared with
prednisone/prednisolone in patients with DMD,
including less decline in distance walked, less time
needed for 4-stair climbing, and greater delay in
LoA. The availability of treatments that have the
potential to alter the natural history of DMD supports the need for early diagnosis in patients with
this disease.
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